A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms PanRVD
- 15 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
- 10 Aug 2018 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 10 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.